Monitoring of human papillomavirus vaccination

Clinical and Experimental Immunology

Volumn 163, Issue 1, 2011, Pages 17-25

  Dillner, J ^a   Arbyn, M ^b   Unger, E ^c   Dillner, L ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cancer prevention; Effectiveness; Genotyping; Surveillance

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY RESPONSE; ANUS CANCER; CANCER CONTROL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; DRUG MONITORING; EYE CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; LARYNX CANCER; LARYNX PAPILLOMATOSIS; NONHUMAN; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS LIKE AGENT; VULVA CANCER;

ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; MALE; MASS SCREENING; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 78649721287     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04268.x     Document Type: Review

References (96)

1. Carter JJ, Koutsky LA, Wipf GC et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996174:927-36.
2. Carter J, Koutsky L, Hughes J et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000181:1911-19.
3. Ho G, Studentsov Y, Bierman R, Burk R. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 200413:110-16.
4. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 19976:233-7.
5. Lehtinen M, Luukkaala T, Wallin K-L et al. Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 200122:117-24.
6. Dillner J, Kallings I, Brihmer C et al. Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis 1996173:1394-8.
7. Dillner J, Lehtinen M, Björge T et al. Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 199789:1293-9.
8. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 19999:423-30.
9. Orth G, Favre M. Human papillomaviruses. Biochemical and biologic properties. Clin Dermatol 19853:27-42.
10. Hines J, Ghim S, Christensen N et al. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 199455:13-20.
11. Roden R, Hubbert N, Kirnbauer R, Christensen N, Lowy D, Schiller J. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 199670:3298-301.
12. Christensen ND, Kreider JK, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology 1991181:572-9.
13. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 199973:6188-90.
14. Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, crossneutralizing epitopes. Virology 2000270:254-7.
15. White W, Wilson S, Palmer-Hill F et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 199973:4882-9.
16. Greenstone HL, Nieland JD. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 199895:1800-5.
17. Nieland J, Da Silva D, Velders M et al. Chimeric papillomavirus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 199973:145-52.
18. Jagu S, Karanam B, Gambhira R et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009101:782-92.
19. Zhou J, Sun XJ, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV156 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991185:251-7.
20. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 199486:494-9.
21. Man S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Exp Rev Mol Med 19981998:1-19.
22. Niedergang F, Didierlaurent A, Kraehenbuhl J, Sirard J. Dendritic cells: the host Achille's heel for mucosal pathogens? Trends Microbiol 200412:79-88.
23. Stern P. Recent developments in human papillomavirus vaccines. Exp Opin Investig Drugs 200413:959-71.
24. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 200193:284-92.
25. Brown DR, Bryan JT, Schroeder JM et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001184:1183-6.
26. Ault KA, Giuliano AR, Edwards RP et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 200422:3004-7.
27. Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001183:1485-93.
28. Koutsky L, Ault K, Wheeler C et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002347:1645-51.
29. Harper D, Franco E, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004364:1757-65.
30. Villa L, Costa R, Petta C et al. Prohylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 20056:271-8.
31. Mao C, Koutsky L, Ault K et al. Efficacy of human papillomavirus 16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006107:18-27.
32. Harper D, Franco E, Wheeler C et al. Sustained efficacy up to 4-5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised trial. Lancet 2006367:1247-55.
33. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE II) Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical intraepithelial neoplasia. N Engl J Med 2007356:1915-27.
34. Garland SM, Hernandez-Avila M, Wheeler CM et al.Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE I) Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007356:1928-43.
35. Paavonen J, Naud P, Salmerón J et al.for the HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009374:301-14.
36. Hildesheim A, Herrero R, Wacholder S et al.Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007298:743-53.
37. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008110:S18-25.
38. Wheeler CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPVtypes 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009199:936-44.
39. Brown DR, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPVtypes 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009199:926-35.
40. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 20022:342-50.
41. Steenbergen RD, De Wilde J, Wilting SM, Brink AA, Snijders PJ, Meijer CJ. HPV-mediated transformation of the anogenital tract. J Clin Virol 200532 (Suppl. 1):S25-33.
42. Stern P. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol 200532 (Suppl. 1):S72-81.
43. Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol 200910:975-80.
44. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Exp Opin Biol Ther 20088:421-39.
45. Stanley M. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Exp Rev Vaccines 20032:381-9.
46. Schiller J, Nardelli-Haefliger D. Chapter 17: second generation HPV vaccines to prevent cervical cancer. Vaccine 200624:147-53.
47. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 200826:6529-41.
48. Lévy-Bruhl D, Bousquet V, King LA et al.Country Specific VENICE Gate Keepers and Contact Points. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur J Cancer 200945:2709-13.
49. Lacey C, Lowndes C, Shah K. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 200624:35-41.
50. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE. Carcinogenicity of human papillomaviruses. Lancet Oncol 20056:204.
51. Pagliusi S, Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 200423:569-78.
52. Lowy D, Frazer I. Chapter 16: prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 200331:111-16.
53. Villa L, Ault K, Giuliano A et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 200624:5571-83.
54. Harper DM. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol 2008110:S11-17.
55. Joura EA, Kjaer SK, Wheeler CM et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 200826:6844-51.
56. Koutsky L, Holmes K, Critchlow C et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992327:1272-8.
57. Woodman C, Collins S, Winter H et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001357:1831-6.
58. Winer R, Lee S, Hughes J, Adam D, Kiviat N, Koutsky L. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. J Epidemiol 2003157:218-26.
59. French K, Barnabas R, Lehtinen M, Kontula O, Dillner J, Garnett G. Strategies for the introduction of HPV vaccination: modelling the optimum age and sex specific pattern of vaccination in Finland. Br J Cancer 200796:514-18.
60. Ryding J, French KM, Naucler P, Barnabas RV, Garnett GP, Dillner J. Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine 200826:5263-8.
61. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in cervical cancer screening. J Clin Virol 200738:189-97.
62. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 200537:S3-9.
63. Solomon D, Papillo JL, Davey DDCytopathology Education and Technology Consortium. Statement of human papillomavirus DNA test utilization. Arch Pathol Lab Med 2009133:1276-7.
64. Hughes J, Garnett G, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 200213:631-9.
65. Taira A, Neukermans C, Sanders G. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 200410:1915-23.
66. Garnett G. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 200519 (Suppl. 1):S97-106.
67. Garnett G, Kim J, French K, Goldie S. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 200624:178-86.
68. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 20063:1-9.
69. Lehtinen M. Vaccination against human papillomaviruses shows great promise. Lancet 2004364:1731-2.
70. Lehtinen M. Preparations for implementing human papillomavirus vaccination should begin. Euro Surveill 200510:1-2.
71. Lehtinen M, Apter D, Dubin G et al. Enrolment of 22 000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 200617:517-21.
72. Lehtinen M, Idanpaan-Heikkila I, Lunnas T et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS 200617:237-46.
73. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009200:166-71.
74. Munoz N, Bosch FX, Sanjose SD et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003348:518-27.
75. Munoz N, Bosch F, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004111:278-85.
76. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 200718:1708-15.
77. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 200718:1425-7.
78. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci USA 199794:6571-6.
79. Silins I, Kallings I, Dillner J. Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 20009:953-9.
80. Rousseau M, Villa L, Costa M, Abrahamowicz M, Rohan T, Franco E. Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Infect 200330:581-7.
81. Mendez F, Munoz N, Posso H et al.Instituto Nacional de Cancerologia Human Papillomavirus Study Group. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis 2005192:1158-65.
82. Silins I, Ryd W, Strand A et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005116:110-15.
83. Pastrana DV, Vass WC, Lowy DR, Schiller JT. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 2001279:361-9.
84. Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 200918:321-30.
85. Nauclér P, Ryd W, Törnberg S et al. HPV type-specific risks of high grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 200797:129-32.
86. Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill 200914:pii: 19119.
87. Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJLM, Beutels P. Introduction of HPV vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Invest 2010(in press).
88. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 200985:499-502.
89. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 200945:2632-9.
90. Parkin D, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 200624 (Suppl. 3):S11-25.
91. Lynge E, Anttila A, Arbyn M, Segnan N, Ronco G. What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. Eur J Cancer 200945:2714-21.
92. Goldie S, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 200496:604-15.
93. Schiller J, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 20042:343-7.
94. Arbyn M, Rebolj M, De Kock IM, Becker N, O'Reilly M, Andrae B. The challenges for organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 200945:2671-8.
95. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006118:1508-14.
96. Quint W, Pagliusi S, Lelie N, DeVilliers E-M, Wheeler CWHO HPV DNA International Collaborative Study Group. Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA. J Clin Microbiol 200644:571-9.